Business Description
PTC Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US69366J2006
Share Class Description:
PTCT: Ordinary SharesTotal Employee Number:
991Description
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.79 | |||||
Equity-to-Asset | -0.06 | |||||
Debt-to-Equity | -2.19 | |||||
Debt-to-EBITDA | -18.38 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.71 | |||||
Beneish M-Score | -1.6 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 26.2 | |||||
3-Year Book Growth Rate | 19 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.82 | |||||
9-Day RSI | 72.16 | |||||
14-Day RSI | 68.63 | |||||
3-1 Month Momentum % | 3 | |||||
6-1 Month Momentum % | -7.47 | |||||
12-1 Month Momentum % | 44.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.44 | |||||
Quick Ratio | 2.36 | |||||
Cash Ratio | 2.05 | |||||
Days Inventory | 309.52 | |||||
Days Sales Outstanding | 89.25 | |||||
Days Payable | 175.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.7 | |||||
Shareholder Yield % | -0.86 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 92.48 | |||||
Operating Margin % | -8.11 | |||||
Net Margin % | -22.58 | |||||
EBITDA Margin % | -2.6 | |||||
FCF Margin % | -62.48 | |||||
OCF Margin % | -26.35 | |||||
ROA % | -6.81 | |||||
ROIC % | -4.78 | |||||
3-Year ROIIC % | 659.45 | |||||
ROC (Joel Greenblatt) % | -54.14 | |||||
ROCE % | -3.52 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 145.29 | |||||
PS Ratio | 9.12 | |||||
EV-to-EBIT | -86.15 | |||||
EV-to-Forward-EBIT | 76.74 | |||||
EV-to-EBITDA | -274.55 | |||||
EV-to-Forward-EBITDA | 58.09 | |||||
EV-to-Revenue | 7.14 | |||||
EV-to-Forward-Revenue | 4.59 | |||||
EV-to-FCF | -11.42 | |||||
Price-to-GF-Value | 2.49 | |||||
Price-to-Median-PS-Value | 1.68 | |||||
Earnings Yield (Greenblatt) % | -1.16 | |||||
FCF Yield % | -6.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PTCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PTC Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 827.11 | ||
| EPS (TTM) ($) | -2.33 | ||
| Beta | 1.2908 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 0.99 | ||
| Volatility % | 43.14 | ||
| 14-Day RSI | 68.63 | ||
| 14-Day ATR ($) | 3.145526 | ||
| 20-Day SMA ($) | 78.7975 | ||
| 12-1 Month Momentum % | 44.63 | ||
| 52-Week Range ($) | 43.175 - 89.8 | ||
| Shares Outstanding (Mil) | 82.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PTC Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PTC Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 120 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 32 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 31 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 09:20 | 70.87 (-0.13%) | ||
| General meeting for 2026 | 2026-06-02 09:00 | 73.80 (+0.71%) | ||
| Guidance call for 2026 | 2026-05-20 10:00 | 70.31 (-0.14%) | ||
| Guidance call for 2026 | 2026-05-12 11:40 | 76.85 (+2.63%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 66.57 (+0.89%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 66.57 (+0.89%) |
Show
Entries
PTC Therapeutics Inc Frequently Asked Questions
What is PTC Therapeutics Inc(PTCT)'s stock price today?
The current price of PTCT is $89.20. The 52 week high of PTCT is $89.80 and 52 week low is $43.18.
When is next earnings date of PTC Therapeutics Inc(PTCT)?
The next earnings date of PTC Therapeutics Inc(PTCT) is 2026-08-07 Est..
Does PTC Therapeutics Inc(PTCT) pay dividends? If so, how much?
PTC Therapeutics Inc(PTCT) does not pay dividend.
Guru Commentaries on NAS:PTCT
No articles.
Press Release
Articles on PTC Therapeutics Inc
No articles.
Headlines
See More- 1
Jun 16, 2026
PTC Therapeutics prices convertible notes for refinancing
Seeking Alpha • 3:38am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers